1. Home
  2. SAFT vs TBPH Comparison

SAFT vs TBPH Comparison

Compare SAFT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safety Insurance Group Inc.

SAFT

Safety Insurance Group Inc.

HOLD

Current Price

$75.90

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$20.87

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFT
TBPH
Founded
1979
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
993.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SAFT
TBPH
Price
$75.90
$20.87
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$27.80
AVG Volume (30 Days)
60.7K
370.5K
Earning Date
02-24-2026
02-25-2026
Dividend Yield
4.84%
N/A
EPS Growth
15.78
N/A
EPS
5.87
0.58
Revenue
$1,231,116,000.00
$80,327,000.00
Revenue This Year
N/A
$70.78
Revenue Next Year
N/A
N/A
P/E Ratio
$12.94
$35.74
Revenue Growth
12.77
27.12
52 Week Low
$67.04
$7.90
52 Week High
$84.20
$21.03

Technical Indicators

Market Signals
Indicator
SAFT
TBPH
Relative Strength Index (RSI) 47.98 68.68
Support Level $74.47 $19.53
Resistance Level $76.44 $21.00
Average True Range (ATR) 1.62 0.82
MACD -0.18 0.12
Stochastic Oscillator 36.20 94.77

Price Performance

Historical Comparison
SAFT
TBPH

About SAFT Safety Insurance Group Inc.

Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: